Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Pigster/Phantom/Matt/PL appreciate your replies, thanks.
I used to dabble (I mean lost money) spread betting via IG but withdrew when they upped the amount of cash you had to put up to cover positions. I didn’t think IG offered positions on AIM listed shares. I’ll look into this and Spreadex tomorrow and may hold off selling any shares for time being.
Thanks Matt. May I ask who I can place that spread between with?
Any drop in price driven by traders getting out tomorrow will present many LTH’s like me with an opportunity.
I plan to sell around £20k’s worth of shares in my Fund & Share account with HL tomorrow and once paid out transfer the cash into my ISA where I’ll re-purchase hopefully at that lower price a couple of days later, assuming the CV & CE RNS hasn’t been published.
Whilst I might have to sell a few more shares than had the share remained around £2.30 I will benefit longer term on the increased tax free gain. I’ve tried doing the maths to work out the difference between the cost of buying my shares back if they rise and the saving in tax-free ISA wrapper to see if it’s worth the risk but it makes my head hurt lol.
GLALTH
None taken PL - will try harder . . . to be funny.
Just to add balance Trip Hop, my Dad passed awAy 6 years ago with Alzheimers, so did my father-in-law and my dear old Mum’s been given a couple of months with two terminal tumours so I don’t need a lecture in mortality. Despite what the Muslims protesting about the Yorkshire teacher sharing THAT cartoon about Mohammed claim, being offended is a choice, not a breach of UK law. It was a joke, get over yourself.
A man takes his wife to get tested for Coronavirus. Two days later, he gets a call from the lab.
Doctor: I'm sorry to inform you that your wife's test results have been mixed up with another patient's. We're not sure if she has COVID-19 or Alzheimer's disease.
Man: So what am I supposed to do now?
Doctor: I'd recommend taking her for a long walk and leaving her, if she finds her way back home, don't open the door.
Happy Easter Avactarians and roll on Tuesday!!
You say you have researched the Company Robbie but I question your understanding of what lies ahead for Avacta? Have you read all the RNS and watched all the Vox interviews with Dr Alistair Smith? They are freely available on Avacta’s website? If so you will know for example the company are not suffering any liquidity issues with £48M in the Bank. That one inane comment lays bare the lazy journalism behind the article you naively published on this BB.
Your first post asked for kindness and with that in mind I’m going to politely ask you not to foul this well-researched board again with poorly-written, inaccurate articles without doing the work yourself and checking what you’ve read. Otherwise you’ll be met with deserved rebukes for appearing as lazy and un-researched as the writer of the piece you chose to promote here.
Have a good day and enjoy the CV results RNS when it lands shortly.
GLA LTH.
What caught my eye was the fact they managed to include three references to Dr Mike Owen stepping down from his role as Non-executive Director of Avacta but continuing as Chair of the Scientific Advisory Board.
Tyche100 - whilst a Union Jack-emblazoned LFT will hit the spot for Boris at his imminent No10 LFT press launch I don’t think it will excite the 260 million people living across the Channel or the rest of the world’s population of 8 Billion. UK population is just a tiny market for Avacta. GLA LTH
I hope the Sellotape is CE marked Pigster - lol!
I lost more money spread betting 10 years ago than I care to remember being one of the 82%. A friend of mine still believes in the advantages of s/b that you highlighted but I argue with him often that regardless of any price movement you only lose money if you sell your shares. Adopting a longer term holding strategy, I prefer share ownership, far less stressful. Each to his own, so GLA.
Looks like breath test for covid and more on the way and has a link with Avacta... Deepverge DVRG has yet to release RNS as this was leaked today by the university! Northumbria University spinout - PulmoBioMed - to develop world-leading medical device .... out today news.... See the link from today. Note world leading ... Deepverge DVRG looking really cheap. In November, PulmoBioMed entered into a partnership agreement with DeepVerge plc, a company specialising in the use of artificial intelligence to detect, analyse and identify more than 2700 pathogens in clinical research, medical device, environmental and life science equipment. The partnership combines the breathalyser PBM-HALE with DeepVerge’s Microtox BT a micro-engineered nano-fluidic chip to detect viruses, bacteria, toxins and parasites in drinking and wastewater and identifies specific targets which includes SARS-CoV-2, within breath condensate samples in less than 90 seconds. This collaboration is the beginning of a joint development program that will use multiplex bio-marker binding agents to analyse breath for 40 other diseases which include cancer, neurodegenerative, respiratory and metabolic conditions.
HTTPS://newsroom.northumbria.ac.uk/pressreleases/new-northumbria-university-spinout-pulmobiomed-to-develop-world-leading-medical-device-3081849
Courtesy of Onehanded over at ADVFN one hour ago:
“ Looks like breath test for covid and more on the way and has a link with Avacta... Deepverge DVRG has yet to release RNS as this was leaked today by the university! Northumbria University spinout - PulmoBioMed - to develop world-leading medical device .... out today news.... See the link from today. Note world leading ... Deepverge DVRG looking really cheap. In November, PulmoBioMed entered into a partnership agreement with DeepVerge plc, a company specialising in the use of artificial intelligence to detect, analyse and identify more than 2700 pathogens in clinical research, medical device, environmental and life science equipment. The partnership combines the breathalyser PBM-HALE with DeepVerge’s “Microtox BT” a micro-engineered nano-fluidic chip to detect viruses, bacteria, toxins and parasites in drinking and wastewater and identifies specific targets which includes SARS-CoV-2, within breath condensate samples in less than 90 seconds. This collaboration is the beginning of a joint development program that will use multiplex bio-marker binding agents to analyse breath for 40 other diseases which include cancer, neurodegenerative, respiratory and metabolic conditions. HTTPS://newsroom.northumbria.ac.uk/pressreleases/new-northumbria-university-spinout-pulmobiomed-to-develop-world-leading-medical-device-3081849
Not necessarily Visainn.
Avacta issued a 10:35 RNS on 30 September last year informing the market how pleased they were that the BAMS assay to detect the SARS-CoV-2 virus had been launched as a research kit1 by its partner Adeptrix.
I am so pleased with my decision to fill my SIPP with shares in Avacta, the gift that keeps on giving. GLA LTH
A prion is a type of protein that can trigger normal proteins in the brain to fold abnormally. Prion diseases can affect both humans and animals and are sometimes spread to humans by infected meat products. The most common form of prion disease that affects humans is Creutzfeldt-Jakob disease (CJD) - aka Mad Cow Disease
“Ray!!
Ray!!
Come quick!” Said Jackie Brown?
One of Tarrantino’s best imho
Onwards and Upwards Avacta!
Ladies and Gentlemen,
Please welcome . . . BAMS!!!
Booom - lol!
You forgot to add the complete absence of our favourite derampers to your list. Funny how they’ve suddenly vanished innit?
£200-ex Chi-nah Party 17th June
I’ll join you PL and book the turn. How about a Tina Turner tribute act belting out “Simply The Best” all bloody night?
Apologies if posted yesterday; if so I missed this very positive Note from Finncap:
“ from FinnCap
Diagnostics licence with Biokit
The licence agreement signed with Biokit, for the use of an Affimer reagent in an in-vitro diagnostics (IVD) product, is the first full commercial agreement within diagnostics. It provides further external endorsement of Avacta’s capabilities and serves as a reminder of the broad application of the Affimer platform outside of therapeutics and SARS-CoV-2. This licence is the third non-therapeutics agreement signed (New England Biolabs – life science research applications in 2018 and Astrea Bioprocessing in 2020) and in line with the building momentum of customer evaluations and development programmes using Affimers. We reiterate our SOTP valuation of 310p, with the key near-term milestone (clinical evaluation of lateral flow SARS CoV-2 test) expected around the end of Q1 2021.
Newsflow. Avacta signed a licence agreement with Biokit, to incorporate Affimer® reagents into an undisclosed Biokit in-vitro diagnostic (IVD) product. Avacta will receive a royalty on future sales (low single digit is typical in the industry), once product development has completed and regulatory approval granted. The agreement also has scope to expand the partnership to include other diagnostic targets and future Affimer-based IVDs.
Biokit is part of Werfen, a privately owned company located near Barcelona, with a global IVD presence. Werfen generated revenues and EBITDA of €1.47bn and €345m in 2019, respectively, of which IVD revenues accounted for €1.29bn (growing at c.7%) – so a very relevant and well respected partner.
Strong endorsement for use of Affimers in diagnostics, following an extensive evaluation by Biokit of certain Affimer reagents designed to detect an undisclosed, albeit key analyte. This is a significant milestone for Avacta as it validates the Affimer reagent platform for diagnostics. It is the first commercial licence agreement reached with a third party in the diagnostics market (Avacta received an undisclosed upfront in 2017 from a top 3 diagnostics company to gain exclusive rights to several Affimer reagents), with Avacta understood to have further Affimers under licensing discussions (5 at the time of its fundraise in June 2020).
Valuation. No changes to forecasts and we reiterate our SOTP target price of 310p. Of this, diagnostics (excluding AffiDX SARS CoV-2 rapid antigen test) account for c.20p (c.£50m) of the valuation. There is clearly scope for this to rise and we reference Bioventix (BVXP: £220m market capitalisation) as an example of the IVD licensing model Avacta is pursuing in conjunction with development of its wholly- owned pipeline of diagnostic products.”
DonaldTrumpsWig
You’ve nailed it with your summary that an accurate, easy-to-use, anterior nasal LFD will put amend to this profligate abuse of public funds. The BBC item was reporting on an article in today’s online Guardian:
No evidence £22bn test-and-trace scheme cut Covid rates in England, say MPs
https://www.theguardian.com/world/2021/mar/10/no-evidence-22bn-test-and-trace-scheme-cut-covid-rates-in-england-say-mps?CMP=Share_iOSApp_Other